- Q3 sales $18.1B vs $17.3B est
- Adj EPS $2.49 vs $2.09 est
- FY revenue guidance raised to $66.8-$67.3B
Merck reported Q3 sales of $18.1B vs $17.3B est, adj EPS $2.49 vs $2.09 est. Raised full-year guidance. Keytruda sales $8.6B. Stock rose 5.3%. Investors focused on pipeline beyond 2028 Keytruda patent loss.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.